ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2919

Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort

Angélique Lemaire1,2, Vincent Sobanski2,3,4,5, Jonathan Giovannelli6, Eric Hachulla1,2,4,5, Sylvain Dubucquoi4,7, Marc Lambert1,2,4,5, Pierre-Yves Hatron1,2,6 and David Launay1,2,4,5, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, 2CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, 3CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, 4Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, 5Inserm, U995, F-59000 Lille, France, Lille, France, 6Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France, 7CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Antiphospholipid antibodies, systemic sclerosis and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Antiphospholipid antibodies (aPL) have been found in patients with various autoimmune and rheumatic diseases, including systemic sclerosis (SSc). However, in the absence of clinical events classically associated with the antiphospholipid syndrome, their significance remains unclear. This study aimed to determine the prevalence of aPL in a cohort of SSc patients, and to assess their clinical associations. AL and VS have contributed equally to this work.

Methods: A total of 249 adult patients who fulfilled 2013 ACR/EULAR criteria for SSc were consecutively included between October 2014 and January 2016. Patients were tested for lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2glycoproteine I (anti-β2GpI) antibodies. Positive titer was defined as ≥ 10 UGPL/mL (aCL) or ≥ 10 UA/mL (anti-β2GpI). aPL positivity was defined if at least one of the three antibodies was positive. Clinical associations between aPL positivity and thrombosis event, obstetrics event, pulmonary arterial hypertension (PAH) and digital ulcer were studied using binomial logistic regressions. Adjustments were done (i) a priori for gender, age, SSc subtype and tobacco history, and (ii) for the characteristics that differed significantly between aPL positive and negative patients. Similar analyzes were performed considering the titers of aCL and anti-β2GpI rather than the aPL status. Because these variables had a majority of zero values, they were categorized, as follows: (i) 0, ≥1 and <5, ≥5 and ≤20 UGPL/mL for aCL, and (ii) 0, ≥1 and <5, ≥5 and <10, ≥10 and ≤100 UA/mL for anti-β2GpI.

Results: The 249 patients were predominantly female (82.3%), with limited cutaneous SSc (81.5%). One or more type of aPL was present in 16 patients leading to a prevalence of 6.4% (95% confidence interval (CI) [3.4-9.5]). aPL positivity was associated with venous thrombosis in univariate analysis (OR=3.91; 95%CI [0.98-13.53]; p=0.027); there was a trend towards an association in multivariate analysis (OR=3.24; 95%CI [0.87-10.9]; p=0.064). aPL positivity was associated with miscarriage in multivariate analysis (OR=4.31; 95%CI [1.09-16.33]; p=0.031). We did not find any association between aPL positivity and PAH or digital ulcer. Titers of aCL ≥5 UGPL/mL were associated with PAH (OR=6.35; 95%CI [1-41.1]; p=0.043) and venous thrombosis (OR=3.69; 95%CI [0.98-12.9]; p=0.043) in multivariate analysis. Titers of anti-β2GpI ≥10 UA/mL and miscarriage were associated (OR=5.25; 95%CI [1.04-27.1]; p=0.041).

Conclusion: This study found a prevalence of aPL in SSc of 6.4% (95%CI [3.4-9.5]) in a French cohort. aPL positivity was associated with venous thrombosis and miscarriage. These data provide additional insights into the vascular involvement of SSc.  

 

Univariate analysis

 

Multivariate analysis

 

OR

95%CI

p

 

OR

95%CI

p

Arterial or venous thrombosis

2.92

0.82-9.50

0.085

 

2.59

0.77-8.12

0.108

Arterial thrombosis

2.56

0.43-10.54

0.160

 

2.14

0.87-10.9

0.307

Venous thrombosis

3.91

0.98-13.53

0.027

 

3.24

0.42-8.52

0.064

Miscarriage

2.84

0.67-11.11

0.136

 

4.31

1.09-16.33

0.031

Digital ulceration

0.31

0.03-1.47

0.150

 

0.45

0.07-1.86

0.327

PAH

0.97

0.02-7.26

1

 

0.73

0.04-4.43

0.776

 


Disclosure: A. Lemaire, None; V. Sobanski, None; J. Giovannelli, None; E. Hachulla, None; S. Dubucquoi, None; M. Lambert, None; P. Y. Hatron, None; D. Launay, None.

To cite this abstract in AMA style:

Lemaire A, Sobanski V, Giovannelli J, Hachulla E, Dubucquoi S, Lambert M, Hatron PY, Launay D. Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-antiphospholipid-antibodies-and-their-clinical-associations-in-systemic-sclerosis-data-from-a-french-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-antiphospholipid-antibodies-and-their-clinical-associations-in-systemic-sclerosis-data-from-a-french-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology